Your browser doesn't support javascript.
loading
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
Jamshidi, Ahmadreza; Vojdanian, Mahdi; Soroush, Mohsen; Akbarian, Mahmoud; Aghaei, Mehrdad; Hajiabbasi, Asghar; Mirfeizi, Zahra; Khabbazi, Alireza; Alishiri, Gholamhosein; Haghighi, Anousheh; Salimzadeh, Ahmad; Karimzadeh, Hadi; Shirani, Fatemeh; Fard, Mohammad Reza Hatef; Nazarinia, MohammadAli; Soroosh, Soosan; Anjidani, Nassim; Gharibdoost, Farhad.
Afiliação
  • Jamshidi A; Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Vojdanian M; Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Soroush M; Rheumatology Department, AJA University of Medical Sciences, Tehran, Iran.
  • Akbarian M; Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Aghaei M; Golestan Rheumatology Research Center (GRRC), Golestan University of Medical Sciences, Gorgan, Iran.
  • Hajiabbasi A; Department of Rheumatology, Guilan Rheumatology Research Center, School of Medicine, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran.
  • Mirfeizi Z; Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Khabbazi A; Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Alishiri G; Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Haghighi A; Rheumatology Department, Iran University of Medical Sciences, Tehran, Iran.
  • Salimzadeh A; Rheumatology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Karimzadeh H; Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Shirani F; Department of Rheumatology, Iran University of Medical Sciences, Tehran, Iran.
  • Fard MRH; Rheumatology Ward, Internal Medicine Department, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Nazarinia M; Shiraz Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Soroosh S; Rheumatology Department, AJA University of Medical Sciences, Tehran, Iran.
  • Anjidani N; Medical Department, Orchid Pharmed Company, Tehran, Iran.
  • Gharibdoost F; Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. gharibdoostfarhad@gmail.com.
Arthritis Res Ther ; 24(1): 161, 2022 06 30.
Article em En | MEDLINE | ID: mdl-35773713
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoporose / Osteoporose Pós-Menopausa / Conservadores da Densidade Óssea / Medicamentos Biossimilares Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Arthritis Res Ther Assunto da revista: REUMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoporose / Osteoporose Pós-Menopausa / Conservadores da Densidade Óssea / Medicamentos Biossimilares Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Arthritis Res Ther Assunto da revista: REUMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã